Ganlee's Biweekly GLP-1RA Injection Accepted for Review by China Drug Regulator

On September 2, the official website of the Center for Drug Evaluation under the National Medical Products Administration showed that Ganlee Pharmaceutical's independently developed glucagon-like peptide-1 receptor agonist (GLP-1RA) biweekly injection, Bofanglutide (development code: GZR18), has had its marketing application formally accepted. The drug is intended for long-term weight management in obese or overweight patients. As a biweekly formulation, the acceptance information for its marketing application has been made public on the center's website.